Literature DB >> 31043378

Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network.

Amanda Valeta-Magara1, Abhilash Gadi1, Viviana Volta1, Beth Walters1, Rezina Arju1, Shah Giashuddin2, Hua Zhong3, Robert J Schneider4,3,5.   

Abstract

Inflammatory breast cancer (IBC) is a highly aggressive form of breast cancer that displays profound cancer stem cell (CSC) and mesenchymal features that promote rapid metastasis. Another hallmark of IBC is high infiltration of M2 tumor-associated (immune-suppressing) macrophages. The molecular mechanism that drives these IBC phenotypes is not well understood. Using patient breast tumor specimens, breast cancer cell lines, and a patient-derived xenograft model of IBC, we demonstrate that IBC strongly expresses IL8 and growth-regulated oncogene (GRO) chemokines that activate STAT3, which promotes development of high levels of CSC-like cells and a mesenchymal phenotype. We also show that IBC expresses high levels of many monocyte recruitment and macrophage polarization factors that attract and differentiate monocytes into tumor-promoting, immune-suppressing M2-like macrophages. The M2 macrophages in turn were found to secrete high levels of IL8 and GRO chemokines, thereby creating a feed-forward chemokine loop that further drives an IBC epithelial-to-mesenchymal transition. Our study uncovers an intricate IBC-initiated autocrine-paracrine signaling network between IBC cells and monocytes that facilitates development of this highly aggressive form of breast cancer. SIGNIFICANCE: This study uncovers a signaling network in which IBC cells commandeer macrophages to become tumor-promoting, and they in turn drive IBC cells to be more cancer stem-like, mesenchymal, and aggressive.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/79/13/3360/F1.large.jpg. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31043378      PMCID: PMC7331114          DOI: 10.1158/0008-5472.CAN-17-2158

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer.

Authors:  So Yeon Park; Hee Eun Lee; Hailun Li; Michail Shipitsin; Rebecca Gelman; Kornelia Polyak
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

2.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.

Authors:  Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine
Journal:  J Natl Cancer Inst       Date:  2005-07-06       Impact factor: 13.506

3.  Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.

Authors:  Nicole J McCarthy; Xiaowei Yang; Ilona R Linnoila; Maria J Merino; Stephen M Hewitt; Allyson L Parr; Soonmyung Paik; Seth M Steinberg; Dan P Hartmann; Nejib Mourali; Paul H Levine; Sandra M Swain
Journal:  Clin Cancer Res       Date:  2002-12       Impact factor: 12.531

4.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

5.  A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype.

Authors:  K L van Golen; S Davies; Z F Wu; Y Wang; C D Bucana; H Root; S Chandrasekharappa; M Strawderman; S P Ethier; S D Merajver
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

6.  Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification.

Authors:  Ilse Van der Auwera; Steven J Van Laere; Gert G Van den Eynden; Ina Benoy; Peter van Dam; Cecile G Colpaert; Stephen B Fox; Helen Turley; Adrian L Harris; Eric A Van Marck; Peter B Vermeulen; Luc Y Dirix
Journal:  Clin Cancer Res       Date:  2004-12-01       Impact factor: 12.531

7.  CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.

Authors:  Kwan Ho Tang; Stephanie Ma; Terence K Lee; Yuen Piu Chan; Pak Shing Kwan; Carol M Tong; Irene O Ng; Kwan Man; Ka-Fai To; Paul B Lai; Chung-Mau Lo; Xin-Yuan Guan; Kwok Wah Chan
Journal:  Hepatology       Date:  2012-01-13       Impact factor: 17.425

8.  Inflammatory breast cancer cells are constitutively adapted to hypoxia.

Authors:  Deborah Silvera; Robert J Schneider
Journal:  Cell Cycle       Date:  2009-10-23       Impact factor: 4.534

9.  Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.

Authors:  Dongwei Zhang; Tiffany A LaFortune; Savitri Krishnamurthy; Francisco J Esteva; Massimo Cristofanilli; Ping Liu; Anthony Lucci; Balraj Singh; Mien-Chie Hung; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

10.  Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer.

Authors:  Deborah Silvera; Rezina Arju; Farbod Darvishian; Paul H Levine; Ladan Zolfaghari; Judith Goldberg; Tsivia Hochman; Silvia C Formenti; Robert J Schneider
Journal:  Nat Cell Biol       Date:  2009-06-14       Impact factor: 28.824

View more
  42 in total

Review 1.  Inflammatory Breast Cancer: a Separate Entity.

Authors:  Jennifer M Rosenbluth; Beth A Overmoyer
Journal:  Curr Oncol Rep       Date:  2019-08-15       Impact factor: 5.075

2.  Comprehensive Characterization of Necroptosis-Related lncRNAs in Bladder Cancer Identifies a Novel Signature for Prognosis Prediction.

Authors:  Kuang XiaYu; Cai GuoGang; Li CanXuan; Xie WeiBin
Journal:  Dis Markers       Date:  2022-06-06       Impact factor: 3.464

Review 3.  Potential Pro-Tumorigenic Effect of Bisphenol A in Breast Cancer via Altering the Tumor Microenvironment.

Authors:  Youngjoo Kwon
Journal:  Cancers (Basel)       Date:  2022-06-19       Impact factor: 6.575

4.  Autofluorescence Imaging of 3D Tumor-Macrophage Microscale Cultures Resolves Spatial and Temporal Dynamics of Macrophage Metabolism.

Authors:  Tiffany M Heaster; Mouhita Humayun; Jiaquan Yu; David J Beebe; Melissa C Skala
Journal:  Cancer Res       Date:  2020-10-22       Impact factor: 12.701

5.  Tubular STAT3 Limits Renal Inflammation in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Amandine Viau; Maroua Baaziz; Amandine Aka; Manal Mazloum; Clément Nguyen; E Wolfgang Kuehn; Fabiola Terzi; Frank Bienaimé
Journal:  J Am Soc Nephrol       Date:  2020-04-01       Impact factor: 10.121

6.  Adipose-Derived Stem Cells Promote Bone Coupling in Bisphosphonate-Related Osteonecrosis of the Jaw by TGF-β1.

Authors:  Xian Dong; Linhai He; Xiaolong Zang; Yang He; Jingang An; Baoping Wu; Xinhua Liu; Hongsen Bi; Yi Zhang; E Xiao
Journal:  Front Cell Dev Biol       Date:  2021-05-12

7.  Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors.

Authors:  François Bertucci; Laurys Boudin; Pascal Finetti; Christophe Van Berckelaer; Peter Van Dam; Luc Dirix; Patrice Viens; Anthony Gonçalves; Naoto T Ueno; Steven Van Laere; Daniel Birnbaum; Emilie Mamessier
Journal:  Oncoimmunology       Date:  2021-05-23       Impact factor: 8.110

Review 8.  Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression.

Authors:  Jing Jin; Yi Li; Qijie Zhao; Yue Chen; Shaozhi Fu; JingBo Wu
Journal:  Cell Commun Signal       Date:  2021-05-06       Impact factor: 5.712

9.  High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations.

Authors:  Qinghua Wang; Yichen Yang; Meng Yang; Xiangchun Li; Kexin Chen
Journal:  Aging (Albany NY)       Date:  2020-06-03       Impact factor: 5.682

Review 10.  Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance.

Authors:  Łukasz Zadka; Damian J Grybowski; Piotr Dzięgiel
Journal:  Cell Oncol (Dordr)       Date:  2020-06-02       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.